ADMA Biologics/$ADMA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Ticker
$ADMA
Sector
Primary listing
Employees
685
Headquarters
Website
ADMA Biologics Metrics
BasicAdvanced
$3.5B
16.96
$0.86
0.45
-
Price and volume
Market cap
$3.5B
Beta
0.45
52-week high
$25.67
52-week low
$13.50
Average daily volume
3.7M
Financial strength
Current ratio
7.128
Quick ratio
3.524
Long term debt to equity
18.433
Total debt to equity
19.278
Interest coverage (TTM)
19.97%
Profitability
EBITDA (TTM)
175.009
Gross margin (TTM)
54.71%
Net profit margin (TTM)
42.87%
Operating margin (TTM)
34.19%
Effective tax rate (TTM)
-34.46%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
21.76%
Return on equity (TTM)
63.17%
Valuation
Price to earnings (TTM)
16.963
Price to revenue (TTM)
7.071
Price to book
8.03
Price to tangible book (TTM)
8.1
Price to free cash flow (TTM)
85.072
Free cash flow yield (TTM)
1.18%
Free cash flow per share (TTM)
0.171
Growth
Revenue change (TTM)
27.62%
Earnings per share change (TTM)
205.35%
3-year revenue growth (CAGR)
55.28%
10-year revenue growth (CAGR)
54.87%
3-year earnings per share growth (CAGR)
32.81%
10-year earnings per share growth (CAGR)
-6.47%
What the Analysts think about ADMA Biologics
Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.
Bulls say / Bears say
ADMA received FDA approval for its innovative yield enhancement production process on April 28, 2025, becoming the first U.S. producer of plasma-derived products to receive this approval and paving the way for a 20% increase in production yields. (GlobeNewswire)
In Q2 2025, ADMA began commercial-scale manufacturing using its FDA-approved yield enhancement process, with initial batches delivering the targeted 20%+ increase in finished immunoglobulin output, supporting future margin expansion. (GlobeNewswire)
In Q2 2025, the company completed a $300 million syndicated debt refinancing led by J.P. Morgan, featuring a $75 million term loan and a $225 million revolving credit facility, significantly reducing borrowing costs and increasing strategic flexibility. (GlobeNewswire)
ADMA’s revenue growth slowed to 14% year-over-year in Q2 2025, a sharp deceleration compared to the 40% increase recorded in Q1 2025, which may indicate waning demand momentum. (GlobeNewswire)
Management’s 2025 outlook did not incorporate any expected impact from the FDA-approved yield enhancement process or the pre-clinical SG-001 hyperimmune globulin candidate, highlighting the uncertainty about realizing these growth drivers in the short term. (GlobeNewswire)
As a company producing plasma-derived biologics, ADMA is exposed to significant risks of transmitting infectious agents, including viruses and prion diseases such as Creutzfeldt-Jakob disease, which could prompt recalls or regulatory actions. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
ADMA Biologics Financial Performance
Revenues and expenses
ADMA Biologics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ADMA Biologics stock?
ADMA Biologics (ADMA) has a market cap of $3.5B as of November 08, 2025.
What is the P/E ratio for ADMA Biologics stock?
The price to earnings (P/E) ratio for ADMA Biologics (ADMA) stock is 16.96 as of November 08, 2025.
Does ADMA Biologics stock pay dividends?
No, ADMA Biologics (ADMA) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next ADMA Biologics dividend payment date?
ADMA Biologics (ADMA) stock does not pay dividends to its shareholders.
What is the beta indicator for ADMA Biologics?
ADMA Biologics (ADMA) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.